Yanchuang Capital
6th Floor, Ritan International Hotel, No.17 Ritan North Road, Chaoyang District, Beijing, China
Overview
"Yan Chuang Capital", the full name of "Yanyuan Innovation Capital Group", was founded in June 2010, formerly known as "Yanyuan Capital Group". A high-tech enterprise investment and capital operation platform co-sponsored by Peking University alumni who have transformed achievements. Yanchuang Capital always takes value investment as the core, adhering to the corporate philosophy of "Integrity and character, customer-centered, and ultimate work", based on the excavation of China's outstanding achievements in the historical trend of economic growth, technological catch-up, and corporate growth. Enterprises and entrepreneurs; take capital as the main channel and provide empowerment services, and create greater value for investors through common growth and win-win development with outstanding enterprises and entrepreneurs.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Avistone Pharmaceuticals
Participated · Series B · Jan 2024
Avistone Biotechnology is an oncology company focused on developing targeted therapies for patients with unmet medical needs, with a lead asset PLB1001 (Vebreltinib) that targets MET tyrosine kinase activity. PLB1001 recently received conditional approval from the NMPA for MET exon 14 skipping NSCLC in China. The company also develops PLB1004, an EGFR tyrosine kinase inhibitor including activity against EGFR exon20 insertion mutations. Avistone has built a commercial sales and marketing team covering 25 provinces, nearly 1,000 hospitals, and hundreds of commercial companies and retail outlets in China. The company plans to use recent financing to support clinical research and development, internal combination studies, accelerated screening of new molecules, and expansion of clinical studies and commercialization in the United States. Avistone positions itself to continue advancing its pipeline and commercialization efforts while expanding global clinical development.
- Laekna Therapeutics
Participated · Series D · May 2022
Laekna leverages a platform that has enabled the rapid development of 14 innovative drug candidates and has initiated six clinical programs, three of which are multi-regional including one pivotal trial. The company is focused on developing next-generation therapies addressing standard-of-care-resistant cancers and liver diseases. Its two core product candidates are AKT kinase inhibitor afuresertib (LAE002) and a clinical-stage CYP17/CYP11B2 dual inhibitor (LAE001). These candidates cover three differentiated mechanisms: targeted therapy, hormonal therapy, and immuno-oncology therapy. The most advanced program is an open-label, randomized, multi-regional Phase 2 PROFECTA-II trial of afuresertib, described as the world’s first registration-directed clinical trial of an AKT kinase inhibitor to treat platinum-resistant ovarian cancer. Laekna is led by CEO Dr. Chris Lu and intends to use new funds to accelerate development of its core candidates.
- EpimAb Biotherapeutics
Participated · Series C · Mar 2021
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing proprietary bispecific antibody therapeutics using its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The company focuses on oncology and other high‑value therapeutic areas and is building a pipeline of both clinical and preclinical bispecific programs. Its lead candidates—EMB-01 (EGFR/cMET), EMB-02 (PD-1/LAG-3) and EMB-06 (CD3/BCMA)—are advancing through clinical development in China, the U.S. and Australia. Proceeds from the Series C will fund ongoing clinical development of these three assets and expand the company’s pipeline of novel bispecifics and other biologics. EpimAb maintains research and manufacturing facilities in Shanghai and Suzhou and intends to selectively license platform and pipeline assets to partners worldwide. The company emphasizes translating its FIT-Ig platform into differentiated clinic-ready molecules with global potential. EpimAb Biotherapeutics is a Shanghai-based R&D biotech focused on generating bispecific antibody therapeutics via its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The company is advancing a clinical PhI/II program, EMB01, and is building a pipeline concentrated on immuno-oncology and other high-unmet-need areas. Management includes founder and CEO Chengbin Wu, COO/CBO Stephan Lensky, and CMO Bin Peng, who lead discovery, financing/BD, and translational/clinical development respectively. With the Series B close, EpimAb plans to expand development and manufacturing capacity, adding a new CMC site in Suzhou for process development and pilot manufacturing. The company also pursues selective licensing of its platform to diversify its pipeline and partner globally. Financially, the Series B brings recent financing to $74M and total funding to over $100M to support near-term clinical and manufacturing initiatives. EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai, founded in 2015, focused on generating bispecific molecules with antibody-like properties using its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The FIT-Ig technology is designed to be more potent, less immunogenic and easier to manufacture. EpimAb is building a pipeline of novel bispecific antibody therapeutics centered on immuno-oncology and other areas with high unmet medical need, and seeks to diversify via selective licensing and strategic partnerships. The company says its platform was validated through early partnerships with biopharmaceutical companies in China and abroad. Management plans to advance its lead oncology program toward the clinic, anticipating submission of an IND and the start of a first clinical trial in 2018. Leadership includes founder and CEO Dr. Chengbin Wu, inventor of FIT-Ig®, and Dr. Stephan Lensky as COO and CBO.
Team
No current team members are available.